On the afternoon of June 12, 2026, the 3rd Medical Device R&D Forum was held at the Beijing Zhongguancun Exhibition Center Conference Hall. Co-hosted by the Medtec China project team (under Informa Markets, UK) and MedTech (Siyu MedTech), and co-organized by the Zhongguancun Biomedical Industry Alliance, the forum focused on active interventional medical devices and related innovative technologies. Discussions centered on hot fields including neuromodulation, brain-computer interfaces, cochlear implants, artificial hearts, interventional robots, AI medical devices, and biomaterials, exploring new trends and pathways for innovative medical device R&D and technology transfer.

Keynote Presentations: Spotlight on Active Interventional Devices and Innovative Transformation

At the opening session, Zhang Xin, Marketing Director of Medtec China (under Informa Markets, UK), delivered an address.

She stated that medical device innovation is moving from single-point technological breakthroughs toward systemic innovation, placing higher demands on R&D, manufacturing, registration, clinical validation, and industrial collaboration. As an important platform serving the medical device industry over the long term, Medtec China will continue connecting R&D, engineering, manufacturing, and industrial resources to accelerate the transfer and implementation of innovative achievements. She expressed hope that this forum would promote upstream-downstream collaborative innovation across the industry chain and jointly drive high-quality development of China's medical device industry.

Special Note: The 2026 International Medical Device Design and Manufacturing Technology Exhibition (Medtec China) will be held from September 1–3 at Halls N1–N4, Shanghai New International Expo Center. Visitor registration is now open, with a limited number of free admission tickets available. Scan the QR code at the end of this article to register.

Zhang Xin, Marketing Director of Medtec China

Qin Haiqiang, Deputy Director of the Technology Transfer Office at Beijing Tiantan Hospital, Capital Medical University, Chief Physician and Professor of Neurology, shared insights on medical-engineering interdisciplinary innovation in the field of neurological diseases.

As brain health receives increasing attention, there remain substantial unmet clinical needs in areas such as stroke and neurodegenerative diseases. Combining Tiantan Hospital's innovation practices in recent years, Qin Haiqiang introduced the hospital's experience in technology transfer system construction, medical-engineering collaboration mechanism exploration, and innovation project incubation, and shared transformation explorations in projects such as low-field magnetic resonance imaging and rapid genetic testing. He believes that clinical needs are an important starting point for innovation, and only products that truly solve clinical problems can achieve long-term value and sustainable development.

Qin Haiqiang, Deputy Director of the Technology Transfer Office at Beijing Tiantan Hospital, Capital Medical University, Chief Physician and Professor of Neurology

Pan Tao, Head of the Otology Group in the Department of Otolaryngology at Peking University Third Hospital, Chief Physician, shared insights on the development and technology transfer of cochlear implants.

From single-channel to multi-channel cochlear implants, and with domestic products gradually maturing in recent years, cochlear implants have become an important treatment modality enabling patients with severe to profound sensorineural hearing loss to recover hearing. Combining the development history of China's cochlear implant industry, Pan Tao analyzed the critical links from basic research, technology breakthroughs, clinical validation, to industrial implementation, and shared clinical experience in cochlear implant revision and re-implantation. He stated that as technology continues to advance and clinical demand grows, the domestic cochlear implant industry is welcoming new development opportunities.

Pan Tao, Head of the Otology Group in the Department of Otolaryngology at Peking University Third Hospital, Chief Physician

Liu Shikun of Beijing PINS Medical Co., Ltd. shared insights on the development of implantable neuromodulation and brain-computer interface industries.

Neuromodulation has gradually become an important treatment modality for diseases such as Parkinson's disease, epilepsy, and chronic pain, while the development of brain-computer interfaces is driving neurological disease diagnosis and treatment into a new stage. Combining PINS Medical's R&D practice in products such as deep brain stimulators (DBS), Liu Shikun shared the current development status of the neuromodulation industry and future technological evolution directions. He believes that as sensing, decoding, and closed-loop control capabilities continue to improve, brain-computer interface and neuromodulation technologies will further integrate to provide patients with more precise and intelligent treatment solutions.

Liu Shikun, Beijing PINS Medical Co., Ltd.

Tang Yue, former Deputy Director of the Surgical Management Committee at Fuwai Hospital, National Center for Cardiovascular Diseases, shared reflections on medical innovation development in the AI era, drawing on over twenty years of experience in medical device innovation, technology transfer, and preclinical research.

He believes that China's medical device industry has gradually moved from early follow-on innovation toward independent innovation, with new technologies such as artificial intelligence and digital twins accelerating entry into medical scenarios, bringing new opportunities for industry development. Regarding innovation pathway selection, Tang Yue emphasized the importance of original innovation and disruptive innovation. He stated that in the future, medical device enterprises need to conduct R&D around real clinical needs, promote innovation achievement transfer on the basis of ensuring safety and efficacy, and achieve the developmental leap from following, parallel running, to leading through continuous technological accumulation and internationalization deployment.

Tang Yue, Former Deputy Director of the Surgical Management Committee at Fuwai Hospital, National Center for Cardiovascular Diseases

Liu Tao, Professor at the School of Biological Science and Medical Engineering, Beihang University, and Director of the AI Medical Device Center at the National Clinical Research Center for Neurological Diseases, shared insights on the development of intelligent diagnosis and treatment equipment in the brain health field.

Combining diagnosis and treatment needs for major brain diseases such as stroke, Liu Tao introduced his team's research achievements in fields such as intelligent brain disease diagnosis, neurological function assessment, AI-assisted decision-making, and intelligent medical equipment. He believes that the deep integration of artificial intelligence, big data, and brain science is driving profound changes in brain disease diagnosis and treatment models. Future brain health industry development requires not only technological breakthroughs but also the construction of a complete transformation system from scientific research innovation to clinical application.

Liu Tao, Professor at the School of Biological Science and Medical Engineering, Beihang University

Li Guangsong, Vice President and Co-Founder of Shaoxing Meio Cardinav Medical Technology Co., Ltd., shared insights on development trends in cardiac interventional surgical robots. She introduced that as cardiovascular interventional therapy continues to evolve toward precision and complexity, robotic technology is becoming an important tool for improving surgical precision and safety. Combining the company's R&D progress in fields such as cardiac electrophysiology navigation robots and magnetic navigation robots, Li Guangsong analyzed the technical challenges and industrial opportunities currently facing cardiac interventional robots. She stated that as artificial intelligence, navigation and positioning, and automatic control technologies continue to mature, cardiac interventional robots are expected to further improve surgical efficiency and treatment quality.

Li Guangsong, Vice President and Co-Founder of Shaoxing Meio Cardinav Medical Technology Co., Ltd.

Tang Zhaohuai, Senior Principal Engineer in the R&D Department of BrioHealth Technologies, shared insights on the development journey of domestic fully magnetically levitated artificial hearts. Facing the enormous clinical needs of patients with advanced heart failure, fully magnetically levitated artificial hearts have become the current internationally mainstream technical route, with core value lying in improving blood compatibility, reducing complication risks, and enhancing patients' long-term survival quality. Combining over ten years of R&D practice at BrioHealth Technologies, Tang Zhaohuai reviewed the development journey of domestic fully magnetically levitated artificial hearts from independent R&D to approval and market launch, as well as continuous innovation in magnetic levitation control, fluid dynamics optimization, and miniaturization design. Currently, related products have completed hundreds of clinical applications and are simultaneously advancing overseas clinical studies, demonstrating the development potential of domestic high-end life support equipment.

Tang Zhaohuai, Senior Principal Engineer in the R&D Department of BrioHealth Technologies

Liu Shenghui, Chief Scientific Officer of SinoVision Technology (Beijing) Co., Ltd., shared insights on the clinical value and innovative applications of weight-bearing CT. She introduced that while traditional supine CT can present human structural information, for certain diseases significantly affected by gravity, there remains a gap between imaging presentation and real-world conditions. Combining multiple clinical cases, Liu Shenghui demonstrated the application value of weight-bearing CT in fields such as spinal degeneration, pelvic injury, pelvic floor dysfunction, and pulmonary function assessment. She stated that weight-bearing CT provides physicians with new perspectives for observing human structural and functional changes, helping to improve the precision of disease diagnosis and treatment decision-making.

Liu Shenghui, Chief Scientific Officer of SinoVision Technology (Beijing) Co., Ltd.

Pan Yuwei, Director of the Medical Device Center at the Functional Materials Institute of the Yangtze River Delta National Innovation Center, Ph.D. in Polymer Materials from Tongji University, combined biomaterials R&D and technology transfer practice to share the project initiation logic and methodology for innovative medical device projects in early-stage R&D. He believes that medical device innovation should be built on real clinical needs, while market space, payment systems, and regulatory requirements should be considered upfront. Combining multiple project cases, Pan Yuwei analyzed key issues in product definition, technical route selection, and industrialization advancement. He stated that precise project initiation, adequate pre-research, and industrialization pathway design are important prerequisites for the successful implementation of innovative medical device projects.

Pan Yuwei, Director of the Medical Device Center at the Functional Materials Institute of the Yangtze River Delta National Innovation Center, Ph.D. in Polymer Materials from Tongji University

Cai Yuchen, Deputy General Manager of Tuowei Mixin Data Technology (Nanjing) Co., Ltd., shared insights on AI applications in cardiovascular intervention. He believes that the value of medical AI lies not only in completing image analysis and auxiliary measurements, but more importantly in integrating into clinical workflows and establishing a complete closed loop from preoperative assessment, intraoperative decision-making, to postoperative outcome feedback. Combining the team's practical experience in the TAVR preoperative planning field, Cai Yuchen introduced how AI helps physicians complete critical links such as anatomical modeling, device selection, and risk assessment, and continuously optimizes model capabilities through real-world data. He stated that in the future, medical AI will become an important auxiliary tool for physicians, providing stronger support for precision diagnosis and treatment and innovative device R&D.

Cai Yuchen, Deputy General Manager of Tuowei Mixin Data Technology (Nanjing) Co., Ltd.

Conclusion

From neuromodulation and brain-computer interfaces to artificial hearts, from cochlear implants and interventional robots to AI medical devices, this forum comprehensively presented the current development status and industry trends in the active interventional device field and related innovative technologies.

As medical device innovation enters deep waters, how to connect critical links such as clinical needs, technology R&D, registration and review, and industrialization implementation has become an important topic for innovative medical devices to achieve success.

As an important component of the 2026 Global MedTech Conference Series, the 3rd Medical Device R&D Forum gathered experts, scholars, and enterprise representatives from hospitals, universities, research institutes, and industry, engaging in in-depth exchanges on medical-engineering integration, technology transfer, and industrial collaboration, providing new ideas and inspiration for innovative medical device R&D and transformation.

With this, the 3rd Medical Device R&D Forum concluded successfully. In the future, MedTech (Siyu MedTech) will continue to follow progress in medical device innovation R&D and technology transfer, witnessing together with industry colleagues more innovative achievements moving toward clinical application and serving patients.

June 12, 2026